Buyback yield (TTM)
2.34%
Shareholder yield (TTM)
2.59%
5Y share count change
-4.1%
Buyback spend (TTM)
$596M
Cumulative buybacks
$2.12B
Key takeaways
- West Pharmaceutical Services (WST) repurchased about $596M of stock over the trailing twelve months.
- Diluted share count is down 4.1% over the last ~5 fiscal years — buybacks are net-shrinking the share base.
- TTM buyback ÷ stock-based-comp ratio of 18.27× — repurchases more than cover SBC dilution.
- Cash buyback spend has compounded at +2.0% per year over the latest 5-year window.
- TTM repurchases used about 159% of free cash flow remaining after dividends.
Dividend & buyback yield over time for West Pharmaceutical Services (WST)
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Diluted vs basic shares (annual) for West Pharmaceutical Services (WST)
Diluted weighted-average shares are the EPS denominator — a falling count means buybacks are outpacing SBC dilution.
Year-over-year change in diluted shares for West Pharmaceutical Services (WST)
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Cash buyback spend over time for West Pharmaceutical Services (WST)
Latest: $134M
Overview
In 2025, West Pharmaceutical Services (WST) buyback spend totalled $134M – plunged 76.4% year-over-year.
Over 2020–2025 (5 years), West Pharmaceutical Services buyback spend expanded at a +2.0% compound annual rate, with mixed annual results across the window.
West Pharmaceutical Services buyback spend plunged from $567M in 2024 to $134M in 2025, a 76.4% drawdown.
2024 marks the peak buyback spend at $567M, with the historical low of $0.00 recorded in 1991.
West Pharmaceutical Services Buyback Spend 2025: $134M
In 2025, West Pharmaceutical Services reported buyback spend of $134M, plunged 76.4% below 2024.
West Pharmaceutical Services Buyback Spend 2024: $567M
West Pharmaceutical Services buyback spend in 2024 was $567M, grew 25.6% from 2023. This figure represents the highest annual value in the available history.
West Pharmaceutical Services Buyback Spend 2023: $451M
2023's buyback spend for West Pharmaceutical Services came in at $451M, surged 103.1% from 2022.
West Pharmaceutical Services Buyback Spend 2022: $222M
West Pharmaceutical Services posted buyback spend of $222M in 2022, surged 46.3% from 2021.
West Pharmaceutical Services Buyback Spend 2021: $152M
West Pharmaceutical Services buyback spend in 2021 was $152M.
See more financial history for West Pharmaceutical Services (WST).
Buyback, SBC & dilution history
Buyback spend, SBC, net dilution effect, and share count.
| 2025 | $134M | $23.8M | $110M | 0.67% | 72.7M | -1.4% | |
| 2024 | $567M | $18.7M | $548M | 2.37% | 73.7M | -2.1% | |
| 2023 | $451M | $23.3M | $428M | 1.73% | 75.3M | -0.7% | |
| 2022 | $222M | $23.7M | $199M | 1.27% | 75.8M | -0.7% | |
| 2021 | $152M | $37.5M | $114M | 0.43% | 76.3M | +0.7% | |
| 2020 | $121M | $34M | $87.4M | 0.58% | 75.8M | +0.5% | |
| 2019 | $85.3M | $24.4M | $60.9M | 0.77% | 75.4M | 0.0% | |
| 2018 | $70.8M | $15.1M | $55.7M | 0.98% | 75.4M | -0.5% | |
| 2017 | $74.4M | $16.1M | $58.3M | 1.02% | 75.8M | +1.1% | |
| 2016 | $55.9M | $19.5M | $36.4M | 0.90% | 75M | +1.6% | |
| 2015 | $5.6M | $29.6M | -$24M | 0.13% | 73.8M | +1.4% | |
| 2014 | $4.1M | $18.6M | -$14.5M | 0.11% | 72.8M | +2.0% | |
| 2013 | $5.2M | $21.2M | -$16M | 0.15% | 71.4M | -0.6% | |
| 2012 | $4.7M | $15.5M | -$10.8M | 0.25% | 71.8M | -3.0% | |
| 2011 | $3.5M | $8.4M | -$4.9M | 0.27% | 74M | +0.8% | |
| 2010 | $2.1M | $7.8M | -$5.7M | 0.15% | 73.4M | +1.1% | |
| 2009 | $1.3M | $7.5M | -$6.2M | 0.10% | 72.6M | +0.6% | |
| 2008 | $5.2M | $6.4M | -$1.2M | 0.42% | 72.2M | -0.3% | |
| 2007 | $43M | $0.00 | $43M | 3.29% | 72.4M | +7.7% | |
| 2006 | $0.00 | $0.00 | $0.00 | — | 67.2M | +3.4% | |
| 2005 | $100K | $0.00 | $100K | 0.01% | 65M | +5.5% | |
| 2004 | $100K | $0.00 | $100K | 0.01% | 61.6M | +5.8% | |
| 2003 | $0.00 | $0.00 | $0.00 | — | 58.2M | +0.7% | |
| 2002 | $100K | $0.00 | $100K | 0.03% | 57.8M | +0.7% | |
| 2001 | $100K | $0.00 | $100K | 0.03% | 57.4M | -0.4% | |
| 2000 | $10.8M | $0.00 | $10.8M | — | 57.6M | -4.2% | |
| 1999 | $18.1M | $0.00 | $18.1M | — | 60.2M | -8.8% | |
| 1998 | $60.4M | $0.00 | $60.4M | — | 66M | -0.4% | |
| 1997 | $0.00 | $0.00 | $0.00 | — | 66.3M | +0.9% | |
| 1996 | $0.00 | $0.00 | $0.00 | — | 65.7M | — | |
| 1995 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1994 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1993 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1992 | $3.3M | $0.00 | $3.3M | — | — | — | |
| 1991 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1990 | $11.3M | $0.00 | $11.3M | — | — | — | |
| 1989 | $5.3M | $0.00 | $5.3M | — | — | — |
- 2025$134M
- 2024$567M
- 2023$451M
- 2022$222M
- 2021$152M
- 2020$121M
- 2019$85.3M
- 2018$70.8M
- 2017$74.4M
- 2016$55.9M
- 2015$5.6M
- 2014$4.1M
- 2013$5.2M
- 2012$4.7M
- 2011$3.5M
- 2010$2.1M
- 2009$1.3M
- 2008$5.2M
- 2007$43M
- 2006$0.00
- 2005$100K
- 2004$100K
- 2003$0.00
- 2002$100K
- 2001$100K
- 2000$10.8M
- 1999$18.1M
- 1998$60.4M
- 1997$0.00
- 1996$0.00
- 1995$0.00
- 1994$0.00
- 1993$0.00
- 1992$3.3M
- 1991$0.00
- 1990$11.3M
- 1989$5.3M
Buybacks vs stock-based compensation for West Pharmaceutical Services (WST)
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 18.27×.
Buybacks vs dividends (share of cash returned) for West Pharmaceutical Services (WST)
How West Pharmaceutical Services splits cash returned to shareholders between dividends and buybacks.
Sector peers by buyback spend
Companies in the same sector as West Pharmaceutical Services, ranked by their latest buyback spend.
| $5.95B | |
| $5.55B | |
| $5.08B | |
| $4.11B | |
| $3B | |
| $980M | |
| $216M | |
| $0.00 |
- $5.95B
- $5.55B
- $5.08B
- $4.11B
- $980M
- $216M
- $0.00
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $375M (TTM FCF − TTM dividends, clamped at zero).
Frequently asked questions
Data & methodology
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
- Buybacks2.34% TTM
- Dividend Profile0.32% yield
- Dividend Calculator
- Dividend Forecast
- Dividend Capture
- Stock Split History4 splits
How this company returns cash to shareholders — buybacks, dividends, and stock splits.